Please supply the following information to download the document - once you've supplied this information you will be able to download any documents from the website in this session and on subsequent visits you will just need to enter your email address.

Name:

Company:

City:

Country:

Email:

Confirm email:

How did you hear about Oliver Wight?:

Occasionally, we would like to send you information that we think you may find relevant and interesting, e.g. workshops, white papers and events. If you would like to receive this information, please tick the box.

Survey of healthcare leaders at European conference highlights top challenges

More than thirty directors and managers from leading healthcare firms across Europe gathered at the Renaissance hotel in Zurich on 3rd May 2018, to discover how to optimise performance in an ever-changing, regulated environment.

A poll of delegates, revealed the top four challenges healthcare companies face in today’s environment are: ‘organisational complexity’, ‘managing uncertainty’, ‘cost competitiveness’ and ‘planning for the long term’.

Oliver Wight Associate, Jerry Shanahan, whose previous CV includes a senior role at medical devices firm, Johnson and Johnson DePuy, said, “The healthcare sector is facing some really tough issues and there is no real surprise in the top four, which of course are all related. In a volatile environment, managing uncertainty is key. To avoid being pulled from one challenge to the next and potentially having different parts of the organisation heading off in different directions, there needs to be a level of integration across the business. Success is all about decision-making; making the right decisions at the right time to determine the future.”

One company clearly making the right decisions is F Hoffman La Roche. Two of its divisions, Roche BioBasel and Roche Roche Kaiseraugst Drug Product Manufacturing Operations in Wurmisweg in Switzerland, each received a Class A Award from Oliver Wight at the event, for their manufacturing operations. Accepting the award for Roche BioBasel, Business Process Manager, Marco Hamann, said: “The Oliver Wight Class A program has allowed us to reduce our release times by two thirds, with a corresponding reduction in inventory. That is a very significant financial gain for us.

Inspirational case study presentations from Almirall and Novartis showed delegates how Class A programs could help them overcome modern day challenges and Ian Anderson, Global Head of the Class A Program for Novartis, believes that ambition plays a key part in an organisation’s success: “Class A is about how to set and sustain a high standard, it’s not just about getting better,” he said.